---
title: "Melanoma is 1.4X more-likely if low Vitamin D – meta-analysis"
slug: "melanoma-is-14x-more-likely-if-low-vitamin-d-meta-analysis"
aliases:
  - "/Melanoma+is+14X+more-likely+if+low+Vitamin+D+–+meta-analysis+May+2023"
  - "/tiki-index.php?page_id=14432"
date: 2023-05-18
categories:
  - "Cancer - Skin"
  - "Meta-analysis of Vitamin D"
---



<!-- {maketoc Title=""} -->
 

---

#### Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis

Melanoma Res . 2023 May 18. [doi: 10.1097/CMR.0000000000000897](https://doi.org/10.1097/CMR.0000000000000897) PDF is behind a $51 paywall

Richard A Shellenberger 1, Sunaina Gowda 1, Heidi Kurn 1, Jeremy Albright 2, MacKenzie H Mayo 1

Cutaneous melanoma (CM) is the deadliest skin cancer, and vitamin D insufficiency has been suggested as a risk factor. We evaluated the relationship between both vitamin D insufficiency and 25-hydroxy vitamin D levels with the incidence and stage of CM. Five databases were searched from inception until 11 July 2022. Inclusion criteria were cohort and case-control studies that reported mean 25-hydroxy vitamin D levels or the presence of vitamin D insufficiency in CM patients and compared with healthy controls; or those that reported vitamin D insufficiency and Breslow tumor depth or the development of metastasis in CM. 

Fourteen studies were included in the analysis. 

Statistically significant relationships were found between 

* vitamin D level <20 ng/dl and incidence of CM <span>[pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02]</span>; 

* lower mean vitamin D level and Breslow depth >1 mm (SMD 0.19, 95% CI 0.11-0.28); and 

* vitamin D level >20 ng/dl and Breslow depth <1 mm (pooled RR 0.69, 95% CI 0.58-0.82). 

Statistical significance was not found in the relationships between vitamin D levels and the presence of metastasis (pooled SMD -0.13, 95% CI, -0.38 to 0.12); or mean vitamin D level and the incidence of CM (pooled SMD -0.39, 95% CI, -0.80 to 0.01). 

We identified an association of increased incidence of CM and vitamin D insufficiency, as well as less favorable Breslow tumor depth with lower levels of vitamin D and the presence of vitamin D insufficiency.

---

##### References

1. Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. <span>[Accessed 11 April 2022]</span>.

1. Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. <span>[Accessed 26 March 2022]</span>.

1. Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... <span>[Accessed 24 March 2022]</span>.

1. Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... <span>[Accessed 22 March 2022]</span>.

1. Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.

1. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.

1. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.

1. Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.

1. Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.

1. Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.

1. Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.

1. Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.

1. Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.

1. Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.

1. Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.

1. Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.

1. Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.

1. Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.

1. Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.

1. Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.

1. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.

1. Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al.  **Vitamin D receptor**  gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.

1. Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.

1. Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.

1. Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.

1. Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.

1. Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.

1. Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.

1. Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.

1. Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.

1. Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.

1. Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.

1. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.

1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.

1. Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.

1. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. <span>[Accessed 24 October 2018]</span>.

1. Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.

1. Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al.  **Vitamin D receptor**  and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.

1. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.

1. Muralidhar S, Filia A, Nsengimana J, Poźniak J, O'Shea SJ, Diaz JM, et al. Vitamin D- **VDR**  signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.

1. Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.

---

#### VitaminDWiki - <a href="/posts/melanoma-might-be-suppressed-by-vitamin-d-many-studies" style="color: red; text-decoration: underline;" title="This post/category does not exist yet: Melanoma might be suppressed by Vitamin D - many studies">Melanoma might be suppressed by Vitamin D - many studies</a>

---

#### VitaminDWiki – [Cancer - Skin](/categories/cancer---skin) category contains

---

#### 85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title

This list is automatically updated

{LIST()}

{list max="150"}

<!-- {filter categories="142"} -->

<!-- {filter field="title" content="melanoma OR cancer"} -->

<!-- {filter type="wiki page"} -->

{sort mode="modification_date_major_desc"}

{OUTPUT(template="table")}

   {tableparams allowtableexpansion="n" shownbitems="y" title=""}

    {column sort="title" label="Title" field="title" mode="raw"}{column}

    {column label="Modified" sort="modification_date_major" field="modification_date_major"}

{OUTPUT}

{FORMAT(name="title")}{display name=title format="objectlink"}{FORMAT}

{FORMAT(name="modification_date_major")}{display name=modification_date_major format="date"}{FORMAT}

{LIST}

<pre style="background-color: #e0e0e0;">
<code class="language-text">
Markdown:
--------

&lt;!-- {maketoc Title=&quot;&quot;} --&gt;
 

---

#### Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis

Melanoma Res . 2023 May 18. [doi: 10.1097/CMR.0000000000000897](https://doi.org/10.1097/CMR.0000000000000897) PDF is behind a $51 paywall

Richard A Shellenberger 1, Sunaina Gowda 1, Heidi Kurn 1, Jeremy Albright 2, MacKenzie H Mayo 1

Cutaneous melanoma (CM) is the deadliest skin cancer, and vitamin D insufficiency has been suggested as a risk factor. We evaluated the relationship between both vitamin D insufficiency and 25-hydroxy vitamin D levels with the incidence and stage of CM. Five databases were searched from inception until 11 July 2022. Inclusion criteria were cohort and case-control studies that reported mean 25-hydroxy vitamin D levels or the presence of vitamin D insufficiency in CM patients and compared with healthy controls; or those that reported vitamin D insufficiency and Breslow tumor depth or the development of metastasis in CM. 

Fourteen studies were included in the analysis. 

Statistically significant relationships were found between 

* vitamin D level &lt;20 ng/dl and incidence of CM &lt;span&gt;[pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02]&lt;/span&gt;; 

* lower mean vitamin D level and Breslow depth &gt;1 mm (SMD 0.19, 95% CI 0.11-0.28); and 

* vitamin D level &gt;20 ng/dl and Breslow depth &lt;1 mm (pooled RR 0.69, 95% CI 0.58-0.82). 

Statistical significance was not found in the relationships between vitamin D levels and the presence of metastasis (pooled SMD -0.13, 95% CI, -0.38 to 0.12); or mean vitamin D level and the incidence of CM (pooled SMD -0.39, 95% CI, -0.80 to 0.01). 

We identified an association of increased incidence of CM and vitamin D insufficiency, as well as less favorable Breslow tumor depth with lower levels of vitamin D and the presence of vitamin D insufficiency.

---

##### References

1. Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. &lt;span&gt;[Accessed 11 April 2022]&lt;/span&gt;.

1. Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. &lt;span&gt;[Accessed 26 March 2022]&lt;/span&gt;.

1. Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... &lt;span&gt;[Accessed 24 March 2022]&lt;/span&gt;.

1. Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... &lt;span&gt;[Accessed 22 March 2022]&lt;/span&gt;.

1. Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.

1. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.

1. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.

1. Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.

1. Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.

1. Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.

1. Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.

1. Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.

1. Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.

1. Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.

1. Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.

1. Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.

1. Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.

1. Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.

1. Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.

1. Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.

1. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.

1. Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al.  **Vitamin D receptor**  gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.

1. Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.

1. Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.

1. Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.

1. Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.

1. Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.

1. Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.

1. Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.

1. Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.

1. Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.

1. Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.

1. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.

1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.

1. Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.

1. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. &lt;span&gt;[Accessed 24 October 2018]&lt;/span&gt;.

1. Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.

1. Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al.  **Vitamin D receptor**  and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.

1. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.

1. Muralidhar S, Filia A, Nsengimana J, Poźniak J, O&#39;Shea SJ, Diaz JM, et al. Vitamin D- **VDR**  signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.

1. Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.

---

#### VitaminDWiki - &lt;a href=&quot;/posts/melanoma-might-be-suppressed-by-vitamin-d-many-studies&quot; style=&quot;color: red; text-decoration: underline;&quot; title=&quot;This post/category does not exist yet: Melanoma might be suppressed by Vitamin D - many studies&quot;&gt;Melanoma might be suppressed by Vitamin D - many studies&lt;/a&gt;

---

#### VitaminDWiki – [Cancer - Skin](/categories/cancer---skin) category contains

---

#### 85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title

This list is automatically updated

{LIST()}

{list max=&quot;150&quot;}

&lt;!-- {filter categories=&quot;142&quot;} --&gt;

&lt;!-- {filter field=&quot;title&quot; content=&quot;melanoma OR cancer&quot;} --&gt;

&lt;!-- {filter type=&quot;wiki page&quot;} --&gt;

{sort mode=&quot;modification_date_major_desc&quot;}

{OUTPUT(template=&quot;table&quot;)}

   {tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}

    {column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}

    {column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}

{OUTPUT}

{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}

{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}

{LIST}

AST Structure:
-------------
├── DivNode
│   full_match: `{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV}`
│   inner_content: `{maketoc Title=&quot;&quot;}`
│   attrs_dict:
│   │   raw_content: (class=&quot;lefth4&quot;)
│   │   class: lefth4
│   children:
│   ├── MakeTocNode
│   │   full_match: `{maketoc Title=&quot;&quot;}`
│   │   inner_content: ``
│   │   attrs_dict:
│   │   │   raw_content:  Title=&quot;&quot;
│   │   │   Title: ├── TextNode
│   full_match: ` `
│   inner_content: ` `├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis`
│   inner_content: `Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis`
│   │   inner_content: `Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis`├── TextNode
│   full_match: `\nMelanoma Res . 2023 May 18. `
│   inner_content: `\nMelanoma Res . 2023 May 18. `├── DoiLinkNode
│   full_match: `doi: 10.1097/CMR.0000000000000897`
│   inner_content: `10.1097/CMR.0000000000000897`├── TextNode
│   full_match: ` PDF is behind a $51 paywall\nRichard A Shellenberger 1, Sunaina Gowda 1, Heidi Kurn 1, Jeremy Albright 2, MacKenzie H Mayo 1\n\nCutaneous melanoma (CM) is the deadliest skin cancer, and vitamin D insufficiency has been suggested as a risk factor. We evaluated the relationship between both vitamin D insufficiency and 25-hydroxy vitamin D levels with the incidence and stage of CM. Five databases were searched from inception until 11 July 2022. Inclusion criteria were cohort and case-control studies that reported mean 25-hydroxy vitamin D levels or the presence of vitamin D insufficiency in CM patients and compared with healthy controls; or those that reported vitamin D insufficiency and Breslow tumor depth or the development of metastasis in CM. \nFourteen studies were included in the analysis. \nStatistically significant relationships were found between \n`
│   inner_content: ` PDF is behind a $51 paywall\nRichard A Shellenberger 1, Sunaina Gowda 1, Heidi Kurn 1, Jeremy Albright 2, MacKenzie H Mayo 1\n\nCutaneous melanoma (CM) is the deadliest skin cancer, and vitamin D insufficiency has been suggested as a risk factor. We evaluated the relationship between both vitamin D insufficiency and 25-hydroxy vitamin D levels with the incidence and stage of CM. Five databases were searched from inception until 11 July 2022. Inclusion criteria were cohort and case-control studies that reported mean 25-hydroxy vitamin D levels or the presence of vitamin D insufficiency in CM patients and compared with healthy controls; or those that reported vitamin D insufficiency and Breslow tumor depth or the development of metastasis in CM. \nFourteen studies were included in the analysis. \nStatistically significant relationships were found between \n`├── ListItemNode
│   full_match: `*vitamin D level &lt;20 ng/dl and incidence of CM [pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02]; `
│   inner_content: `vitamin D level &lt;20 ng/dl and incidence of CM [pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02]; `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `vitamin D level &lt;20 ng/dl and incidence of CM `
│   │   inner_content: `vitamin D level &lt;20 ng/dl and incidence of CM `
│   ├── LinkNode
│   │   full_match: `[pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02]`
│   │   inner_content: `pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02`
│   │   url: `pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `pooled `
│   │   │   inner_content: `pooled `
│   │   ├── BoldNode
│   │   │   full_match: `__RR 1.45__`
│   │   │   inner_content: `RR 1.45`
│   │   │   children:
│   │   │   ├── TextNode
│   │   │   │   full_match: `RR 1.45`
│   │   │   │   inner_content: `RR 1.45`
│   │   ├── TextNode
│   │   │   full_match: `, 95% confidence interval (CI) 1.04-2.02`
│   │   │   inner_content: `, 95% confidence interval (CI) 1.04-2.02`
│   ├── TextNode
│   │   full_match: `; `
│   │   inner_content: `; `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*lower mean vitamin D level and Breslow depth &gt;1 mm (SMD 0.19, 95% CI 0.11-0.28); and `
│   inner_content: `lower mean vitamin D level and Breslow depth &gt;1 mm (SMD 0.19, 95% CI 0.11-0.28); and `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `lower mean vitamin D level and Breslow depth &gt;1 mm (SMD 0.19, 95% CI 0.11-0.28); and `
│   │   inner_content: `lower mean vitamin D level and Breslow depth &gt;1 mm (SMD 0.19, 95% CI 0.11-0.28); and `├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── ListItemNode
│   full_match: `*vitamin D level &gt;20 ng/dl and Breslow depth &lt;1 mm (pooled RR 0.69, 95% CI 0.58-0.82). `
│   inner_content: `vitamin D level &gt;20 ng/dl and Breslow depth &lt;1 mm (pooled RR 0.69, 95% CI 0.58-0.82). `
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `vitamin D level &gt;20 ng/dl and Breslow depth &lt;1 mm (pooled RR 0.69, 95% CI 0.58-0.82). `
│   │   inner_content: `vitamin D level &gt;20 ng/dl and Breslow depth &lt;1 mm (pooled RR 0.69, 95% CI 0.58-0.82). `├── TextNode
│   full_match: `\nStatistical significance was not found in the relationships between vitamin D levels and the presence of metastasis (pooled SMD -0.13, 95% CI, -0.38 to 0.12); or mean vitamin D level and the incidence of CM (pooled SMD -0.39, 95% CI, -0.80 to 0.01). \nWe identified an association of increased incidence of CM and vitamin D insufficiency, as well as less favorable Breslow tumor depth with lower levels of vitamin D and the presence of vitamin D insufficiency.`
│   inner_content: `\nStatistical significance was not found in the relationships between vitamin D levels and the presence of metastasis (pooled SMD -0.13, 95% CI, -0.38 to 0.12); or mean vitamin D level and the incidence of CM (pooled SMD -0.39, 95% CI, -0.80 to 0.01). \nWe identified an association of increased incidence of CM and vitamin D insufficiency, as well as less favorable Breslow tumor depth with lower levels of vitamin D and the presence of vitamin D insufficiency.`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!!References`
│   inner_content: `References`
│   level: `5`
│   children:
│   ├── TextNode
│   │   full_match: `References`
│   │   inner_content: `References`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. [Accessed 11 April 2022].`
│   inner_content: `Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. [Accessed 11 April 2022].`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. `
│   │   inner_content: `Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. `
│   ├── LinkNode
│   │   full_match: `[Accessed 11 April 2022]`
│   │   inner_content: `Accessed 11 April 2022`
│   │   url: `Accessed 11 April 2022`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Accessed 11 April 2022`
│   │   │   inner_content: `Accessed 11 April 2022`
│   ├── TextNode
│   │   full_match: `.`
│   │   inner_content: `.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. [Accessed 26 March 2022].`
│   inner_content: `Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. [Accessed 26 March 2022].`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. `
│   │   inner_content: `Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. `
│   ├── LinkNode
│   │   full_match: `[Accessed 26 March 2022]`
│   │   inner_content: `Accessed 26 March 2022`
│   │   url: `Accessed 26 March 2022`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Accessed 26 March 2022`
│   │   │   inner_content: `Accessed 26 March 2022`
│   ├── TextNode
│   │   full_match: `.`
│   │   inner_content: `.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... [Accessed 24 March 2022].`
│   inner_content: `Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... [Accessed 24 March 2022].`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... `
│   │   inner_content: `Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... `
│   ├── LinkNode
│   │   full_match: `[Accessed 24 March 2022]`
│   │   inner_content: `Accessed 24 March 2022`
│   │   url: `Accessed 24 March 2022`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Accessed 24 March 2022`
│   │   │   inner_content: `Accessed 24 March 2022`
│   ├── TextNode
│   │   full_match: `.`
│   │   inner_content: `.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... [Accessed 22 March 2022].`
│   inner_content: `Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... [Accessed 22 March 2022].`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... `
│   │   inner_content: `Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... `
│   ├── LinkNode
│   │   full_match: `[Accessed 22 March 2022]`
│   │   inner_content: `Accessed 22 March 2022`
│   │   url: `Accessed 22 March 2022`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Accessed 22 March 2022`
│   │   │   inner_content: `Accessed 22 March 2022`
│   ├── TextNode
│   │   full_match: `.`
│   │   inner_content: `.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.`
│   inner_content: `Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.`
│   │   inner_content: `Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.`
│   inner_content: `Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.`
│   │   inner_content: `Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.`
│   inner_content: `Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.`
│   │   inner_content: `Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.`
│   inner_content: `Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.`
│   │   inner_content: `Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.`
│   inner_content: `Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.`
│   │   inner_content: `Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.`
│   inner_content: `Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.`
│   │   inner_content: `Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.`
│   inner_content: `Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.`
│   │   inner_content: `Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.`
│   inner_content: `Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.`
│   │   inner_content: `Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.`
│   inner_content: `Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.`
│   │   inner_content: `Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.`
│   inner_content: `Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.`
│   │   inner_content: `Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.`
│   inner_content: `Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.`
│   │   inner_content: `Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.`
│   inner_content: `Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.`
│   │   inner_content: `Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.`
│   inner_content: `Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.`
│   │   inner_content: `Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.`
│   inner_content: `Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.`
│   │   inner_content: `Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.`
│   inner_content: `Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.`
│   │   inner_content: `Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.`
│   inner_content: `Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.`
│   │   inner_content: `Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.`
│   inner_content: `Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.`
│   │   inner_content: `Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. __Vitamin D receptor__ gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.`
│   inner_content: `Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. __Vitamin D receptor__ gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. `
│   │   inner_content: `Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. `
│   ├── BoldNode
│   │   full_match: `__Vitamin D receptor__`
│   │   inner_content: `Vitamin D receptor`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Vitamin D receptor`
│   │   │   inner_content: `Vitamin D receptor`
│   ├── TextNode
│   │   full_match: ` gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.`
│   │   inner_content: ` gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.`
│   inner_content: `Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.`
│   │   inner_content: `Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.`
│   inner_content: `Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.`
│   │   inner_content: `Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.`
│   inner_content: `Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.`
│   │   inner_content: `Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.`
│   inner_content: `Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.`
│   │   inner_content: `Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.`
│   inner_content: `Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.`
│   │   inner_content: `Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.`
│   inner_content: `Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.`
│   │   inner_content: `Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.`
│   inner_content: `Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.`
│   │   inner_content: `Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.`
│   inner_content: `Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.`
│   │   inner_content: `Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.`
│   inner_content: `Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.`
│   │   inner_content: `Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.`
│   inner_content: `Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.`
│   │   inner_content: `Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.`
│   inner_content: `Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.`
│   │   inner_content: `Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.`
│   inner_content: `Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.`
│   │   inner_content: `Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.`
│   inner_content: `Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.`
│   │   inner_content: `Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [Accessed 24 October 2018].`
│   inner_content: `Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [Accessed 24 October 2018].`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. `
│   │   inner_content: `Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. `
│   ├── LinkNode
│   │   full_match: `[Accessed 24 October 2018]`
│   │   inner_content: `Accessed 24 October 2018`
│   │   url: `Accessed 24 October 2018`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Accessed 24 October 2018`
│   │   │   inner_content: `Accessed 24 October 2018`
│   ├── TextNode
│   │   full_match: `.`
│   │   inner_content: `.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.`
│   inner_content: `Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.`
│   │   inner_content: `Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. __Vitamin D receptor__ and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.`
│   inner_content: `Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. __Vitamin D receptor__ and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. `
│   │   inner_content: `Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. `
│   ├── BoldNode
│   │   full_match: `__Vitamin D receptor__`
│   │   inner_content: `Vitamin D receptor`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Vitamin D receptor`
│   │   │   inner_content: `Vitamin D receptor`
│   ├── TextNode
│   │   full_match: ` and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.`
│   │   inner_content: ` and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.`
│   inner_content: `Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.`
│   │   inner_content: `Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Muralidhar S, Filia A, Nsengimana J, Poźniak J, O&#39;Shea SJ, Diaz JM, et al. Vitamin D-__VDR__ signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.`
│   inner_content: `Muralidhar S, Filia A, Nsengimana J, Poźniak J, O&#39;Shea SJ, Diaz JM, et al. Vitamin D-__VDR__ signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Muralidhar S, Filia A, Nsengimana J, Poźniak J, O&#39;Shea SJ, Diaz JM, et al. Vitamin D-`
│   │   inner_content: `Muralidhar S, Filia A, Nsengimana J, Poźniak J, O&#39;Shea SJ, Diaz JM, et al. Vitamin D-`
│   ├── BoldNode
│   │   full_match: `__VDR__`
│   │   inner_content: `VDR`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `VDR`
│   │   │   inner_content: `VDR`
│   ├── TextNode
│   │   full_match: ` signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.`
│   │   inner_content: ` signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── NumListItemNode
│   full_match: `#Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.`
│   inner_content: `Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.`
│   depth: `1`
│   children:
│   ├── TextNode
│   │   full_match: `Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.`
│   │   inner_content: `Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki - ((Melanoma might be suppressed by Vitamin D - many studies))`
│   inner_content: `VitaminDWiki - ((Melanoma might be suppressed by Vitamin D - many studies))`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki - `
│   │   inner_content: `VitaminDWiki - `
│   ├── LocalLinkNode
│   │   full_match: `((Melanoma might be suppressed by Vitamin D - many studies))`
│   │   inner_content: `Melanoma might be suppressed by Vitamin D - many studies`
│   │   page: `Melanoma might be suppressed by Vitamin D - many studies`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Melanoma might be suppressed by Vitamin D - many studies`
│   │   │   inner_content: `Melanoma might be suppressed by Vitamin D - many studies`├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!VitaminDWiki – ((Cancer - Skin)) category contains`
│   inner_content: `VitaminDWiki – ((Cancer - Skin)) category contains`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `VitaminDWiki – `
│   │   inner_content: `VitaminDWiki – `
│   ├── LocalLinkNode
│   │   full_match: `((Cancer - Skin))`
│   │   inner_content: `Cancer - Skin`
│   │   page: `Cancer - Skin`
│   │   children:
│   │   ├── TextNode
│   │   │   full_match: `Cancer - Skin`
│   │   │   inner_content: `Cancer - Skin`
│   ├── TextNode
│   │   full_match: ` category contains`
│   │   inner_content: ` category contains`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── IncludeNode
│   full_match: `{include page=&quot;Cancer - Skin&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content:  page=&quot;Cancer - Skin&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;
│   │   page: Cancer - Skin
│   │   start: ~tc~ start ~/tc~
│   │   stop: ~tc~ end ~/tc~
│   children:
│   ├── TextNode
│   │   full_match: ``
│   │   inner_content: ``├── HorizontalRuleNode
│   full_match: `\n---\n`
│   inner_content: `---`├── HeadingNode
│   full_match: `!!!!85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title`
│   inner_content: `85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title`
│   level: `4`
│   children:
│   ├── TextNode
│   │   full_match: `85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title`
│   │   inner_content: `85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title`├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── EmphasisNode
│   full_match: `&#39;&#39;This list is automatically updated&#39;&#39;`
│   inner_content: `This list is automatically updated`
│   children:
│   ├── TextNode
│   │   full_match: `This list is automatically updated`
│   │   inner_content: `This list is automatically updated`├── TextNode
│   full_match: `\n{LIST()}\n{list max=&quot;150&quot;}\n`
│   inner_content: `\n{LIST()}\n{list max=&quot;150&quot;}\n`├── FilterNode
│   full_match: `{filter categories=&quot;142&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content: categories=&quot;142&quot;
│   │   categories: 142├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── FilterNode
│   full_match: `{filter field=&quot;title&quot; content=&quot;melanoma OR cancer&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content: field=&quot;title&quot; content=&quot;melanoma OR cancer&quot;
│   │   field: title
│   │   content: melanoma OR cancer├── TextNode
│   full_match: `\n`
│   inner_content: `\n`├── FilterNode
│   full_match: `{filter type=&quot;wiki page&quot;}`
│   inner_content: ``
│   attrs_dict:
│   │   raw_content: type=&quot;wiki page&quot;
│   │   type: wiki page├── TextNode
│   full_match: `\n{sort mode=&quot;modification_date_major_desc&quot;}\n{OUTPUT(template=&quot;table&quot;)}\n   {tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}\n    {column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}\n    {column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}\n{OUTPUT}\n{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}\n{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}\n{LIST}`
│   inner_content: `\n{sort mode=&quot;modification_date_major_desc&quot;}\n{OUTPUT(template=&quot;table&quot;)}\n   {tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}\n    {column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}\n    {column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}\n{OUTPUT}\n{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}\n{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}\n{LIST}`

Original Tiki:
-------------
{DIV(class=&quot;lefth4&quot;)}{maketoc Title=&quot;&quot;}{DIV} 
---
!!!!Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis
Melanoma Res . 2023 May 18. doi: 10.1097/CMR.0000000000000897 PDF is behind a $51 paywall
Richard A Shellenberger 1, Sunaina Gowda 1, Heidi Kurn 1, Jeremy Albright 2, MacKenzie H Mayo 1

Cutaneous melanoma (CM) is the deadliest skin cancer, and vitamin D insufficiency has been suggested as a risk factor. We evaluated the relationship between both vitamin D insufficiency and 25-hydroxy vitamin D levels with the incidence and stage of CM. Five databases were searched from inception until 11 July 2022. Inclusion criteria were cohort and case-control studies that reported mean 25-hydroxy vitamin D levels or the presence of vitamin D insufficiency in CM patients and compared with healthy controls; or those that reported vitamin D insufficiency and Breslow tumor depth or the development of metastasis in CM. 
Fourteen studies were included in the analysis. 
Statistically significant relationships were found between 
*vitamin D level &lt;20 ng/dl and incidence of CM [pooled __RR 1.45__, 95% confidence interval (CI) 1.04-2.02]; 
*lower mean vitamin D level and Breslow depth &gt;1 mm (SMD 0.19, 95% CI 0.11-0.28); and 
*vitamin D level &gt;20 ng/dl and Breslow depth &lt;1 mm (pooled RR 0.69, 95% CI 0.58-0.82). 
Statistical significance was not found in the relationships between vitamin D levels and the presence of metastasis (pooled SMD -0.13, 95% CI, -0.38 to 0.12); or mean vitamin D level and the incidence of CM (pooled SMD -0.39, 95% CI, -0.80 to 0.01). 
We identified an association of increased incidence of CM and vitamin D insufficiency, as well as less favorable Breslow tumor depth with lower levels of vitamin D and the presence of vitamin D insufficiency.
---
!!!!!References
#Institute. USDoHHSNIoHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Common Cancer Sites. Published 2022. https://seer.cancer.gov/statfacts/html/common.html. [Accessed 11 April 2022].
#Institute USDoHHSNIOHNC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Melanoma of the Skin. Published 2022. https://seer.cancer.gov/statfacts/html/melan.html. [Accessed 26 March 2022].
#Oncology ASoC. Types of Cancer. Melanoma Guide. Statistics. Published 2022. https://www.cancer.net/cancer-types/melanoma/statistics#:~:text=Melanoma.... [Accessed 24 March 2022].
#Society AC. Cancer A-Z. Melanoma Skin Cancer. Causes, Risk Factors, and Prevention. Published 2022. https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-preventi.... [Accessed 22 March 2022].
#Paolino G, Moliterni E, Didona D, Garelli V, Corsetti P, Lopez T, et al. Clinicopathological features, vitamin D serological levels and prognosis in cutaneous melanoma of shield-sites: an update. Med Oncol 2015; 32:451.
#Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128:1414–1424.
#Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011; 51:311–336.
#Pinczewski J, Slominski A. The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 2010; 19:860–864.
#Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest 2017; 97:706–724.
#Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One 2014; 9:e112863.
#Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203–211.
#Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, et al. The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. Cancer Causes Control 2011; 22:1471–1482.
#Ene CD, Anghel AE, Neagu M, Nicolae I. 25-OH Vitamin D and interleukin-8: emerging biomarkers in cutaneous melanoma development and progression. Mediators Inflamm 2015; 2015:904876.
#Lombardo M, Vigezzi A, Ietto G, Franchi C, Iori V, Masci F, et al. Role of vitamin D serum levels in prevention of primary and recurrent melanoma. Sci Rep 2021; 11:5815.
#Navarrete-Dechent C, Del Puerto C, Molgó M, González S, Pérez-Mateluna G, Uribe P, et al. Circulating vitamin D-binding protein and free 25-hydroxyvitamin D concentrations in patients with melanoma: a case-control study. J Am Acad Dermatol 2017; 77:575–577.
#Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009; 29:3669–3674.
#Stenehjem JS, Støer NC, Ghiasvand R, Grimsrud TK, Babigumira R, Rees JR, et al. Prediagnostic serum 25-hydroxyvitamin D and melanoma risk. Sci Rep 2020; 10:20129.
#Befon A, Katoulis AC, Georgala S, Katsampas A, Chardalia V, Melpidou A, et al. Serum Total 25-Hydroxyvitamin D levels in patients with cutaneous malignant melanoma: a case-control study in a low-risk Southern European Population. Dermatol Pract Concept 2020; 10:e2020010.
#Timerman D, McEnery-Stonelake M, Joyce CJ, Nambudiri VE, Hodi FS, Claus EB, et al. Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. Oncotarget 2017; 8:6873–6882.
#Gambichler T, Bindsteiner M, Höxtermann S, Kreuter A. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma. Br J Dermatol 2013; 168:625–628.
#Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009; 27:5439–5444.
#Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. __Vitamin D receptor__ gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009; 45:3271–3281.
#Lim A, Shayan R, Varigos G. High serum vitamin D level correlates with better prognostic indicators in primary melanoma: a pilot study. Australas J Dermatol 2018; 59:182–187.
#Lipplaa A, Fernandes R, Marshall A, Lorigan P, Dunn J, Myers KA, et al. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. Br J Cancer 2018; 119:793–800.
#Caini S, Boniol M, Tosti G, Magi S, Medri M, Stanganelli I, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta-analysis. Eur J Cancer 2014; 50:2649–2658.
#Tsai TY, Kuo CY, Huang YC. The association between serum vitamin D level and risk and prognosis of melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2020; 34:1722–1729.
#Piotrowska A, Wierzbicka J, Żmijewski MA. Vitamin D in the skin physiology and pathology. Acta Biochim Pol 2016; 63:17–29.
#Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvitamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Sci Rep 2020; 10:13151.
#Afzal S, Nordestgaard BG, Bojesen SE. Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. J Invest Dermatol 2013; 133:629–636.
#Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic value of 25-hydroxyvitamin D3 levels at diagnosis and during follow-up in melanoma patients. J Natl Cancer Inst 2015; 107:djv264.
#Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, Virtamo J, et al. Pre-diagnostic circulating vitamin D and risk of melanoma in men. PLoS One 2012; 7:e35112.
#Oliveira Filho RS, Oliveira DA, Martinho VA, Antoneli CB, Marcussi LA, Ferreira CE. Serum level of vitamin D3 in cutaneous melanoma. Einstein (Sao Paulo) 2014; 12:473–476.
#Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, et al. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 2014; 23:1220–1229.
#Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
#Bouillon R, Carmeliet G. Vitamin D insufficiency: definition, diagnosis and management. Best Pract Res Clin Endocrinol Metab 2018; 32:669–684.
#Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Published 2014. www.ohri.ca/programs/clinical_epidemiology/oxford.asp. [Accessed 24 October 2018].
#Murad MH. Clinical practice guidelines: a primer on development and dissemination. Mayo Clin Proc 2017; 92:423–433.
#Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. __Vitamin D receptor__ and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127–133.
#Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197–213.
#Muralidhar S, Filia A, Nsengimana J, Poźniak J, O&#39;Shea SJ, Diaz JM, et al. Vitamin D-__VDR__ signaling inhibits Wnt/β-Catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79:5986–5998.
#Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158:495–503.
---
!!!!VitaminDWiki - ((Melanoma might be suppressed by Vitamin D - many studies))
---
!!!!VitaminDWiki – ((Cancer - Skin)) category contains
{include page=&quot;Cancer - Skin&quot; start=&quot;~tc~ start ~/tc~&quot; stop=&quot;~tc~ end ~/tc~&quot;}
---
!!!!85+ VitaminDWiki VDR pages with MELANOMA or CANCER in title
&#39;&#39;This list is automatically updated&#39;&#39;
{LIST()}
{list max=&quot;150&quot;}
{filter categories=&quot;142&quot;}
{filter field=&quot;title&quot; content=&quot;melanoma OR cancer&quot;}
{filter type=&quot;wiki page&quot;}
{sort mode=&quot;modification_date_major_desc&quot;}
{OUTPUT(template=&quot;table&quot;)}
   {tableparams allowtableexpansion=&quot;n&quot; shownbitems=&quot;y&quot; title=&quot;&quot;}
    {column sort=&quot;title&quot; label=&quot;Title&quot; field=&quot;title&quot; mode=&quot;raw&quot;}{column}
    {column label=&quot;Modified&quot; sort=&quot;modification_date_major&quot; field=&quot;modification_date_major&quot;}
{OUTPUT}
{FORMAT(name=&quot;title&quot;)}{display name=title format=&quot;objectlink&quot;}{FORMAT}
{FORMAT(name=&quot;modification_date_major&quot;)}{display name=modification_date_major format=&quot;date&quot;}{FORMAT}
{LIST}
</code>
</pre>
